Generic Drug Facilities Guidance Details Who Self-Identifies, And Who Pays Fees

An FDA draft guidance defines which generic drug manufacturers and other entities must self-report under the new user fee law and which must pay facility fees. It also outlines practical steps companies should take now to meet requirements by deadline.